Simcere Pharmaceutical Group 将来の成長

Future 基準チェック /36

Simcere Pharmaceutical Group利益と収益がそれぞれ年間75.4%と1.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.5% 75.4%なると予測されています。

主要情報

75.4%

収益成長率

75.4%

EPS成長率

Pharmaceuticals 収益成長	21.6%
収益成長率	1.8%
将来の株主資本利益率	15.5%
アナリストカバレッジ	Low
最終更新日	23 Dec 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:S2P - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8,901	1,535	706	1,656	4
12/31/2025	7,790	1,259	608	1,044	5
12/31/2024	6,789	951	822	1,474	5
6/30/2024	6,340	-1,102	240	1,096	N/A
3/31/2024	6,474	-194	-294	623	N/A
12/31/2023	6,608	715	-829	151	N/A
9/30/2023	6,808	1,927	-504	369	N/A
6/30/2023	7,006	3,141	-179	587	N/A
3/31/2023	6,665	2,036	249	971	N/A
12/31/2022	6,324	931	676	1,354	N/A
9/30/2022	5,952	972	673	1,180	N/A
6/30/2022	5,579	1,013	671	1,006	N/A
3/31/2022	5,290	1,260	130	402	N/A
12/31/2021	5,000	1,507	-411	-202	N/A
9/30/2021	4,852	1,274	-481	-200	N/A
6/30/2021	4,703	1,042	-551	-198	N/A
3/31/2021	4,606	856	-404	-51	N/A
12/31/2020	4,509	670	-256	97	N/A
9/30/2020	4,528	699	-314	-6	N/A
6/30/2020	4,548	728	-371	-109	N/A
3/31/2020	4,792	866	-53	332	N/A
12/31/2019	5,037	1,004	265	773	N/A
12/31/2018	4,514	734	441	776	N/A
12/31/2017	3,868	350	N/A	939	N/A

アナリストによる今後の成長予測

収入対貯蓄率: S2Pは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: S2P今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: S2P今後 3 年以内に収益を上げることが予想されます。

収益対市場: S2Pの収益 ( 1.8% ) German市場 ( 5.7% ) よりも低い成長が予測されています。

高い収益成長: S2Pの収益 ( 1.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: S2Pの自己資本利益率は、3年後には低くなると予測されています ( 15.5 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/26 00:19
終値	2024/12/23 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Simcere Pharmaceutical Group Limited 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。16

アナリスト	機関
Sharon Shi	BOCI Research Ltd.
Shaojing Tong	BofA Global Research
Bo Yu	China International Capital Corporation Limited

Simcere Pharmaceutical Group 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Recent updates

Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List

Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Now 22% overvalued

Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Upcoming dividend of CN¥0.16 per share

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022)

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold €271k worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Co-Founder recently sold €360k worth of stock

Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021)

Investor sentiment improves as stock rises 19%

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Now 30% undervalued

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Co-Founder recently bought €957k worth of stock

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021)

Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes

Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China

Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022

Upcoming dividend of CN¥0.15 per share